Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4520 - Generalization and representativeness of phase Ⅲ immune checkpoint inhibitor trials in NSCLC


09 Sep 2017


Poster display session


Shin Hye Yoo


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


S.H. Yoo, M. Kim, B. Keam, T.M. Kim, D. Kim, D.S. Heo

Author affiliations

  • Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR


Abstract 4520


Immune checkpoint inhibitors (ICBs) have become standard treatment in platinum-failed non-small cell lung cancer (NSCLC) based on several phase III studies. Recent randomized phase III trials have led to the approval of ICB. However, strict criteria for patient enrollment of phase III trials raise questions regarding generalization in the real world. The aim of this study was to evaluate whether pivotal phase III trials using ICB represent the real world NSCLC patients.


We reviewed the inclusion/exclusion criteria of 3 practice changing phase III trials (CheckMate057, CheckMate017, KEYNOTE-010). Availability of tumor tissue and other exclusion criteria for KEYNOTE-010 were additionally checked. We retrospectively analyzed the database of stage IIIB or IV NSCLC patients diagnosed from 2011 to 2013 at Seoul National University Hospital (cohort 1). We also analyzed the criteria in 53 NSCLC patients who have treated with nivolumab or pembrolizumab as a routine practice (cohort 2).


Among the 715 NSCLC patients in cohort 1, 499 (69.9%) were ineligible for 3 trials. Reasons for ineligibility were as follows: no platinum doublet 23.6%, lack of tissue 22.7%, the Eastern Cooperative Oncology Group performance status > 1 14.1%, steroid use 18.2%, active central nervous system metastasis 8.3%, hepatitis B or C virus/human immunodeficiency virus 8.0% and no measurable lesion 7.3%. EGFR mutation was more common in ineligible group than eligible group (44.7% vs 19.7%, P 


Only 30.2% of NSCLC patients were eligible for ICB phase III trial. Although ICB have approved for all platinum-failed NSCLC, the real world efficacy of 60% ineligible patients were still unknown. These findings suggest that a huge gap between the practice changing phase III trials and real world NSCLC patients.

Clinical trial identification

Legal entity responsible for the study

Bhumsuk Keam




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.